ZIM
PACB icon

Zacks Investment Management’s Pacific Biosciences PACB Stock Holding History

Zacks Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,170
Closed -$24.5K – 803
2025
Q3 		$24.5K Buy
+19,170
New +$26K ﹤0.01% 738
2024
Q3 		– Sell
-26,479
Closed -$36.3K – 744
2024
Q2 		$36.3K Buy
+26,479
New +$53.5K ﹤0.01% 604

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Zacks Investment Management's PACB Position: Q4 2025 in Review

Zacks Investment Management sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 19,170 shares — an estimated $24.5K sold.

Zacks Investment Management first reported a position in PACB in Q2 2024 and held it in 2 quarters. The position peaked at $36.3K in Q2 2024. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

  • Zacks Investment Management reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
  • Zacks Investment Management sold 19,170 Pacific Biosciences shares in Q4 2025, an estimated $24.5K.
  • Zacks Investment Management first reported a position in Pacific Biosciences in Q2 2024 and held it in 2 quarters.
  • Zacks Investment Management's Pacific Biosciences position peaked at $36.3K in Q2 2024.
  • 215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Zacks Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.